Aging with Thalassemia and Sickle Cell Disease: A Gerontological Model of Accelerated Multimorbidity and...

Thalassemia and sickle cell disease are now increasingly present as lifelong chronic conditions in high-income countries, with growing numbers of patients reaching their 50s and 60s. This demographic shift transforms hemoglobinopathies from childhood-threatening disorders into chronic, multisystem conditions with cumulative morbidity. However, data specifically focused on later-life hemoglobinopathy populations remain limited, fragmented, and often extrapolated from younger cohorts, leaving hematologists and internists relatively unprepared for the functional decline, vulnerability, and geriatric syndromes that can characterize later life in these populations.

This expert opinion narrative review synthesizes available evidence on the intersection of disease-driven pathology (anemia, hemolysis, vasculopathy), long-term treatment burden (transfusion-related iron overload, chelation toxicities), and aging biology (declining physiologic reserve, sarcopenia, cognitive vulnerability) in adults beyond midlife. Given the historical survival patterns in hemoglobinopathies and the inconsistent definition of "older adult" across studies, particularly in sickle cell disease, we use a pragmatic age threshold of >=50 years for the main gerontological framing, while incorporating evidence from cohorts beginning at 40-49 years when that is how the literature defines older hemoglobinopathy populations. We distinguish disease-specific priorities: thalassemia faces myocardial and hepatic iron deposition and endocrine failure, while sickle cell disease confronts cerebrovascular disease, chronic pain, and cardiopulmonary complications. Critically, care targets in later life must extend beyond survival and organ-specific metrics to functional endpoints, disability prevention, cognitive health, and quality of life. A conceptual mapping links mechanisms of hemoglobinopathy to established gerontology constructs, including inflammaging, cellular senescence, and vascular aging, while acknowledging that direct mechanistic evidence in older hemoglobinopathy cohorts remains incomplete.

Three adjustments are necessary in adults beyond midlife: monitoring should prioritize early detection of treatable complications and emerging functional impairment rather than only documenting cumulative organ damage; therapeutic decisions should weigh treatment benefit, treatment burden, comorbidity burden, and goals of care rather than defaulting to pediatric-era protocols; and care systems should embed shared decision-making, palliative principles, and multidisciplinary coordination within primary care networks, with specialist hemoglobinopathy centers functioning as disease-specific hubs rather than stand-alone primary care providers.